BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For
more
information on access to our products, please call our
customer service line at 1-800-469-0261.
BDSI helps develop technologies designed to deliver increased bioavailability in the treatment of serious and debilitating chronic conditions.
BioErodible MucoAdhesive (BEMA®) technology uses a small polymer film applied to the inner lining of the cheek for rapid drug administration. Delivering medication across the mucous membranes, this bioerodible film helps optimize time-sensitive treatments. It is also beneficial for facilitating the administration of drugs where poor oral absorption is an issue.
Total Company Net Revenue of $41 Million , an Increase of 7% versus Prior Year Net Income of $5.2 Million , EBITDA Margin of 22% and Operating Cash Generation of $11 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C. , May 06, 2021 (GLOBE NEWSWIRE) -- BioDelivery
Read moreRALEIGH, N.C. , April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021
Read moreTotal Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million Record Level Profitability with Net Income of $25.7 Million , Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million Conference Call and Webcast Scheduled for 8:30 AM EST Today
Read moreThere are no events to display
Stay up to date on the latest news
Get started now